CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. REDACTED INFORMATION IS INDICATED BY [***].Agreement • April 4th, 2023 • Freeline Therapeutics Holdings PLC • Biological products, (no disgnostic substances) • England
CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. REDACTED INFORMATION IS INDICATED BY [***].Freeline Therapeutics Holdings PLC • April 4th, 2023 • Biological products, (no disgnostic substances) • England
IP Deed of Assignment and License betweenFreeline Therapeutics LimitedandAscend Gene and Cell Therapies Ltd Dated 08 February 2023
CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. REDACTED INFORMATION IS INDICATED BY [***]. TRANSITION SERVICES AGREEMENT between...Transition Services Agreement • April 4th, 2023 • Freeline Therapeutics Holdings PLC • Biological products, (no disgnostic substances) • England
This Transition Services Agreement is made and entered into effective as of 08 February 2023 (the “Effective Date”) by and between:
